Adenosine Receptors and Wound Healing, Revised

Bruce N. Cronstein, M.D.
Professor of Medicine, Pathology and Pharmacology, New York University School of Medicine, 550 First Ave., New York, NY 10016
E-mail: cronsb01@med.nyu.edu

Original review published January 16, 2004; Revised edition published August 17, 2006

This Revised Review is a revision of the review article published, *Vol. 4, 2004*

Recent studies have demonstrated that application of topical adenosine A2A receptor agonists promotes more rapid wound closure and clinical studies are currently underway to determine the utility of topical A2A adenosine receptor agonists in the therapy of diabetic foot ulcers. The effects of adenosine A2A receptors on the cells and tissues of healing wounds have only recently been explored. Here we summarize the evidence indicating that adenosine and selective adenosine agonists, acting at A2A receptors, promote the salutary functions of inflammatory cells, endothelial cells and fibroblasts in stimulating wound healing.

**KEYWORDS:** Adenosine, adenosine receptor, angiogenesis, inflammation, granulation tissue

**INTRODUCTION**

Wound repair is an essential homeostatic mechanism that involves a series of coordinated and overlapping phases: inflammation, angiogenesis, new tissue generation, and tissue reorganization. Aberrant or inadequate wound repair contributes to the disability suffered by patients with diabetes mellitus and is a major problem for patients suffering from venous insufficiency. Our laboratory has recently discovered that topical application of adenosine A2A receptor agonists promotes more rapid wound healing in full-thickness dermal wounds in both normal animals and animals with streptozotocin-induced diabetes mellitus[1]. More recently, Investigational New Drug status has been granted to the highly selective adenosine A2A receptor agonist MRE0094 for use in the treatment of poorly healing foot ulcers in diabetics and initial dose-ranging trials of the drug in patients have begun. To better translate this finding to the clinic, we will review the mechanisms by which adenosine receptor agonists affect the cells involved in wound healing and, thus, promote wound healing.

**PHYSIOLOGIC AND PHARMACOLOGIC ROLES OF ADENOSINE**

Adenosine was first recognized as a physiologic regulator of coronary vascular tone by Drury and Szent-Gyorgy in 1929[2], however it was not until 1970 that Sattin and Rall showed that adenosine regulates cell function via occupancy of specific receptors on the cell surface[3]. It is now clear that there are at
least four different subtypes of adenosine receptor, any one or combination of which may be expressed on
the cell surface (recently reviewed in [4]). Four adenosine receptors have been cloned and the deduced
sequence reveals that all four are members of the large family of 7-transmembrane spanning, G protein
coupled receptors. Three of the adenosine receptor subtypes — A1, A2A, and A2B — are highly conserved
throughout evolution (80–95% sequence homology) whereas A3 receptors vary significantly among
species. In general, A1 receptors are coupled to pertussis toxin-inhibited Gi coupled signal transduction
proteins or directly to ion channels whereas A2 receptors (A2A and A2B) are coupled to Gs- or G12-linked
receptors and stimulate adenylyl cyclase and cAMP accumulation. Adenosine receptors or receptor-
mediated effects have been demonstrated in virtually every tissue or organ examined. Some of the more
prominent physiologic or pharmacologic effects mediated by adenosine receptors include:
neurotransmission (A1 and A2A receptors, the CNS effects of caffeine are thought to result from adenosine
receptor antagonism); modulation of cardiac conduction (A1 receptors, intravenous preparations of
adenosine are licensed for clinical use for the treatment of supraventricular tachycardia); coronary
vasodilation (A2A receptors, infusions of adenosine are licensed for clinical use as a coronary vasodilator
for pharmacologic stress testing); regulation, indirectly, of airway tone (A2B receptors); inhibition of
inflammation (mediates the anti-inflammatory effects of low-dose methotrexate, the most commonly used
second-line agent for the treatment of rheumatoid arthritis (reviewed in [5,6]). Our laboratory first
demonstrated that adenosine modulates neutrophil function via interaction with A1 and A2 receptors and,
when released from cells in increased concentration, inhibits inflammation (reviewed in [6]). In many
tissues and cell types, A1 and A2A receptors have opposing actions not only on cAMP levels but on
function as well (cf. [7,8]). More recently, as noted above, topical application of an adenosine A2A
receptor agonist has been shown to promote wound healing, a process dependent upon the proliferation of
blood vessels, in both normal mice and diabetic rats[1].

THE EFFECTS OF ADENOSINE A2A RECEPTOR AGONISTS ON WOUND HEALING

Our lab has recently reported that topical application of an adenosine A2A receptor agonist increases the
rate at which wounds close[1]. That adenosine A2A receptors were involved in this pharmacologic effect
was demonstrated by the observation that a specific adenosine A2A receptor antagonist, but not
agonists at other adenosine receptors, reversed the effect of the selective A2A receptor agonist
CGS21680 in these studies. Treatment of wounds with an adenosine receptor agonist promoted fibroblast
migration in vitro and in the adenosine receptor agonist-treatment mice there was an increase in matrix and
fibroblast infiltration into the wounds[1]. More recent studies demonstrate that a more highly selective
adenosine A2A receptor agonist, MRE0094, is a more potent promoter of wound healing than recombinant
platelet derived growth factor (becaplermin[9]). The role of adenosine A2A receptors in the promotion of
wound healing was more fully confirmed by the observation that a selective adenosine A2A receptor
agonist promotes wound healing in wild type but not A2A receptor knockout mice[6]. In these studies,
there was a marked increase in the number of blood vessels in the healing wounds of wild type mice
treated with the adenosine A2A receptor agonist as compared to untreated controls. Absence of A2A
receptors was associated with disorganized granulation tissue although wound closure was not delayed in
the knockout mice. In contrast to the work showing that the adenosine A2A receptor promotes wound
healing, Sun and colleagues observed that N6-cyclopentyladenosine, a relatively selective A1 receptor
agonist, promotes wound healing and, interestingly, hair growth[10]. In this study, there was no
confirmation that the high concentrations of the agonist used were indeed selective for A1 receptors or
whether the phenomenon was mediated by adenosine acting at A2A receptors. Interestingly, more recent
studies have suggested that the capacity of minoxidil to stimulate hair growth is mediated by ligation of
adenosine A1 receptors by increased concentrations of endogenously released adenosine[11]. The
literature reviewed here indicates that adenosine, acting at A2A receptors, stimulates the functions of
inflammatory cells, endothelial cells and fibroblasts that promote wound healing.
THE EFFECTS OF ADENOSINE ON INFLAMMATION

As noted above, inflammation is the first step in wound healing. During this phase of tissue repair, necrotic debris is eliminated and bacterial superinfection is prevented by an influx of inflammatory cells, primarily neutrophils at the outset with a predominance of monocytes and lymphocytes later during the course of wound healing. In addition to clearing debris, inflammatory cells release a variety of agents that stimulate the later stages in wound healing. In some pathologic settings, persistent or overly exuberant inflammation may interfere with wound healing. Our laboratory first demonstrated that adenosine, acting at a specific extracellular receptor, inhibits stimulated neutrophil function, release of reactive oxygen species[12,13]. In subsequent studies, it was demonstrated that adenosine receptor occupancy inhibits neutrophil phagocytosis, stimulated neutrophil adhesion to endothelial cells and matrix proteins, and neutrophil-mediated endothelial cell injury[7,14,15]. Early studies demonstrated, by pharmacologic means, that neutrophils express at least two different types of adenosine receptor, one of which (A2 receptors) mediates the inhibition of neutrophil function described above and the other (A1 receptors), when occupied, promotes neutrophil chemotaxis, phagocytosis, and adhesion to vascular endothelial cells[7,14,15,16,17]. These observations have now been confirmed and expanded upon by a large number of laboratories (reviewed in [18]) and it is clear that A2A receptors are the A2 receptors responsible for the suppression of neutrophil function. Although the actions of adenosine A2A receptor occupancy on neutrophil function have generally been ascribed to cAMP (cf. [19]) this signal transduction mechanism appears to hold only in primed (tumor necrosis factor- or endotoxin-stimulated) neutrophils. In contrast, in unprimed neutrophils, the effects of adenosine A2 receptor occupancy modulates neutrophil behavior by a cAMP-protein kinase A-independent mechanism involving activation of a plasma membrane-associated protein phosphatase[20,21].

In addition to its effects on neutrophil function, adenosine — acting at its receptors — also modulates macrophage function. In contrast to neutrophils, both A2A and A3 adenosine receptors appear to be involved in suppression of inflammatory functions of macrophages and there are species-related differences in the effects of these adenosine receptors on macrophage function. Adenosine, acting at A2A receptors, inhibits generation of reactive oxygen species, phagocytosis, cytokine release (TNF, C2, tissue factor/procoagulant), and increases plasminogen activator and IL-10 production (reviewed in [18]). Similar effects have been described for the A3 receptor, although the A3 receptor contribution to adenosine-mediated modulation of inflammation is most notable in cells from mice and is often not demonstrable in human cells.

Adenosine is released from cells and tissues following a variety of insults, e.g., ischemia or inflammation, and presumably is derived from the dephosphorylation of ATP either within the cell or extracellularly[22,23,24,25]. Previous studies, using relatively nonselective adenosine receptor antagonists, have shown that endogenous adenosine regulates inflammation[26] and more recent studies have demonstrated that absence of adenosine A2A receptors increases inflammatory injury[27].

Clearly the use of adenosine or adenosine analogues for the treatment of inflammation has been contemplated and adenosine A2A receptor agonists have been shown to be useful in several models of inflammation[28,29,30,31,32,33]. Nonetheless, fear of the many potential physiologic and pharmacologic effects of adenosine receptor agonists has limited the utility of this approach to suppressing inflammation. Another approach to ligation of adenosine receptors as an anti-inflammatory agent is to promote endogenous adenosine release. The first demonstration that existing anti-inflammatory therapies might make use of endogenous adenosine was reported in 1991 when it was shown, based on in vitro experiments, that low-dose methotrexate therapy, the most commonly used and effective second-line therapy for the treatment of rheumatoid arthritis, induces an increase in adenosine release from injured cells and the adenosine so released inhibits inflammation[34]. Subsequent studies provided support for the hypothesis that adenosine mediates the anti-inflammatory effects of methotrexate provided by observations in an in vivo model of inflammation in which adenosine A2 receptor antagonists and adenosine deaminase reversed the anti-inflammatory effects of methotrexate in mice[35]. In further animal studies, it has been observed that a commonly used adenosine receptor antagonist, caffeine,
reverses the anti-inflammatory effects of methotrexate in the adjuvant arthritis model of inflammation[36] and coffee ingestion (presumably with caffeine) was recently shown to interfere with the anti-inflammatory actions of methotrexate in patients as well[37], an observation that suggests that avoidance of caffeine may enhance the therapeutic effects of methotrexate. In other studies, sulfasalazine, another commonly used second-line agent for the therapy of inflammatory arthritis, shares a mechanism of action with methotrexate; sulfasalazine also promotes the release of adenosine from inflamed cells and tissues and the adenosine released occupies A<sub>2</sub> receptors on inflammatory cells to diminish inflammation[38]. On the basis of these findings and confirmatory studies from other laboratories, specific enzyme (adenosine kinase) inhibitors have been developed that promote adenosine release and suppress inflammation[39,40,41,42].

Interestingly, FK506, a potent and commonly used immunosuppressive agent, has also been reported to inhibit adenosine kinase and adenosine is thought to mediate its effects on acute inflammation[43]. None of the agents described above have been studied in the promotion of wound healing, nor have there been reports that administration of either sulfasalazine or methotrexate interferes or promotes wound healing.

**THE EFFECT OF ADENOSINE RECEPTOR OCCUPANCY ON ANGIOGENESIS AND ENDOTHELIAL CELL FUNCTION**

Previous reports document, by RT-PCR, that cultured human endothelial cells (umbilical vein) express message for all four adenosine receptors[1], although more recent studies document only A<sub>2A</sub> and A<sub>2B</sub> receptor message in human microvascular endothelial cells (Khoa, in press). Although the functional effects of ligation of all of the adenosine receptors on endothelial cells have not been fully explored, it is now clear that adenosine receptor occupancy promotes several potential angiogenic effects when studied in vitro. These studies, from different laboratories, demonstrate that adenosine, acting at specific A<sub>2</sub> receptors, promotes endothelial cell proliferation, migration, and growth factor (VEGF) production[44,45,46,47,48,49]. Moreover, in a recent study it was shown that the effect of adenosine on endothelial cell proliferation is mediated by A<sub>2A</sub> receptors and that cAMP is probably not the second messenger for this phenomenon[49]. Bouma and co-workers have also reported that adenosine, possibly acting at A<sub>3</sub> receptors, diminishes expression of IL-8, a potent angiogenic agent, by stimulated endothelial cell proliferation.
cells[50]. In contrast, others have reported that the cells responsible for the most abundant IL-8 secretion at inflamed sites, macrophage/monocytes, are unaffected by adenosine receptor agonists in their capacity to secrete this angiogenic cytokine[51,52]. Adenosine, acting at A2A and A3 receptors, inhibits tissue factor expression on endothelial cells[53] and promotes NO release by endothelial cells[54]. Recent studies suggest that adenosine A2B receptor occupancy is responsible for promotion of retinal angiogenesis[55,56] although these results may not apply to other vascular beds or to angiogenesis in wounds. Thus, it was recently reported[57] that mice with genetically disrupted A2A receptors (knockouts) form significantly fewer microvessels in healing wounds and in response to mechanical trauma (formation of an air pouch[57]). Furthermore, application of an A2A receptor agonist to wounds increases microvessel formation as compared to vehicle-treated mice, observations that provide the first in vivo evidence that adenosine A2A receptor occupancy promotes angiogenesis. Further studies indicate that the angiogenic effects of adenosine A2A receptor occupancy are mediated both directly on endothelial cells (increased endothelial cell migration and microvascular endothelial cell VEGF production) ([1, 58] and indirectly via promotion of VEGF production by macrophages[59]. Desai and colleagues [60] have also reported evidence to indicate that adenosine A2A receptor occupancy suppresses production of thrombospondin I, a potent inhibitor of angiogenesis and this inhibition is responsible for enhanced vascular tube formation in vitro. Similar to other angiogenic agents, adenosine — acting at A2A receptors — is a potent vasodilator that is also thought to mediate reactive hyperemia in skeletal muscle and the heart. Thus, adenosine, acting via A2A receptors, promotes angiogenesis both directly and indirectly and does so, notably, both in vitro and in vivo.

THE EFFECT OF ADENOSINE A2A RECEPTOR ACTIVATION ON MATRIX PRODUCTION BY FIBROBLASTS

Replacement of the collagenous matrix of the skin and other tissues is an integral part of wound healing. Once the debris and destroyed matrix at the site of injury are eliminated fibroblasts lay down a new matrix. This matrix may be remodeled over a longer period of time and the wound develops the characteristic appearance of a scar. Adenosine A2A receptor occupancy stimulates fibroblasts to synthesize types I and III collagen at an increased level similar to that induced by the growth factor TGF-b [Chan, et al, In Press, Arth. Rheum.]. This observation suggests the possibility that adenosine A2A receptors may play a role in fibrosing conditions and scarring, an hypothesis confirmed by in vivo experiments. Animals lacking A2A receptors or treated with an adenosine A2A receptor antagonist were protected from developing diffuse dermal fibrosis.[Chan, et al, In Press, Arth. Rheum.]. The role of adenosine A2A receptors is unclear in tissues outside of the skin. Prior studies have demonstrated that adenosine A2B receptors regulate production of collagen in pulmonary and cardiac fibroblasts [61-64].

CONCLUSION

Recent studies indicate that adenosine A2A receptor agonists are useful in promoting more rapid wound healing in mice. Beneficial effects of adenosine A2A receptor agonists on all aspects of wound healing — inflammation, angiogenesis, and tissue regeneration — have been observed and probably contribute to promotion of wound closure in both normal healthy mice and diabetic animals as well. There remains an unmet need for agents that will promote wound healing in patients with diabetes and other conditions associated with poor wound healing and it is possible that topical adenosine receptor agonists may help fill this need.
ACKNOWLEDGMENTS

This work was supported by grants from the National Institutes of Health (AR41911, GM56268, AA13336); a grant from King Pharmaceuticals Inc.; the General Clinical Research Center (M01RR00096) and by the Kaplan Cancer Center.

REFERENCES


Submit your manuscripts at http://www.hindawi.com